ShanghaiTech Expands Faculty Search Across Immunology, Structural Biology, and Drug Discovery
ShanghaiTech University is widening its faculty search with a cluster of tenure-track and tenured openings that span biomedicine, life science, and therapeutic discovery. The posting cuts across three research hubs inside the university ecosystem: the School of Life Science and Technology, the Shanghai Institute for Advanced Immunochemical Studies, and the iHuman Institute. Each unit is recruiting investigators who can build independent programs while contributing to a broader research agenda that links basic biology to translational science.
The scale of the search is unusual in one important sense: it is not centered on a single disease area or a single platform. Instead, the openings reach from infection and immunity to structural biology, computational science, medicinal chemistry, and neurobiology. For a university still building its international research profile, that breadth signals a deliberate strategy to assemble faculty who can work across mechanism, technology, and drug development without treating those domains as separate silos.
Recruitment Focus Follows Disease Mechanism and Therapeutic Design
At the School of Life Science and Technology, the university is seeking faculty in biomedicine and pharmacology, developmental and regenerative biology, genomics, metabolism and physiology, molecular and cellular biology, neuroscience, computational structural biology, and infection and immunology. The emphasis on these fields reflects a modern biomedical model: understanding disease at the level of cells, pathways, and molecular architecture before moving toward intervention. That logic matters because many of the most challenging human diseases now require investigators who can move from target identification to mechanism-based therapy in a single research program.
The Shanghai Institute for Advanced Immunochemical Studies places even sharper emphasis on disease-oriented discovery. Its recruitment priorities include autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, axial spondyloarthritis, and ulcerative colitis, along with anti-tumor immunity and infectious diseases including tuberculosis, coronavirus, and flavivirus infections. Those are not random categories. They represent areas where immune dysregulation, host-pathogen interactions, and therapeutic resistance create persistent gaps in treatment. A faculty member working in these domains would be expected to do more than describe biology; the expectation is to generate ideas that can mature into drug candidates.
The institute also signals strong interest in modern discovery methods: AI-driven drug design, de novo protein design, bioinformatics, medicinal chemistry, chemical biology, and drug modality development. In practical terms, that means the next generation of faculty is expected to pair disease biology with platform science. A researcher studying autoimmunity, for example, might also need to understand how a computational pipeline or protein engineering approach can alter the pace at which a therapeutic hypothesis becomes testable.
GPCR Research Sits at the Center of the iHuman Strategy
The iHuman Institute is pushing a similarly integrated model, with a recruitment call focused on GPCR biology and the technologies that support it. GPCRs remain among the most valuable drug targets in pharmacology because they sit at the interface of extracellular signals and intracellular responses, shaping processes that range from neurobiology to immune regulation. Faculty openings at iHuman include cryo-ET with AI-based data analysis and Cryo-FIB/SEM volume imaging, AI for drug discovery, and chemical biology, pharmacology, cell biology, and neurobiology as applied to GPCR research.
One sentence captures the scientific direction of that program: structural biology is no longer being treated as a descriptive tool alone. By pairing cryo-electron tomography with artificial intelligence, the institute is betting on a workflow that can resolve molecular organization more quickly and with greater biological context than older structural methods allowed. In a drug discovery setting, that can shorten the distance between structural observation and hypothesis generation, especially when target conformation influences ligand behavior or signaling bias.
The presence of advanced core facilities strengthens that model. The campus environment includes high-throughput screening, super-resolution imaging, cryo-electron microscopy, biological mass spectrometry, nuclear magnetic resonance, and high-performance computing. For faculty recruits, those resources can lower the barrier to launching ambitious programs. For the institution, they create a shared infrastructure that can support research programs in structural pharmacology, chemical biology, and translational medicine with less duplication and more collaboration.
Tenure-Track Expectations Reflect an International Research Model
Across all three units, the hiring criteria are consistent. Candidates are expected to have a strong research record over the past five years, the ability to establish independent laboratories, and the capacity to contribute to undergraduate and graduate teaching. Competitive startup funds, laboratory space matched to research needs, and benefits including housing support are part of the package. Several units also specify support for research associates and postdoctoral fellows, a detail that matters because early laboratory momentum often depends on staffing before grants arrive.
The university’s language also makes clear that it is recruiting for independence, not just technical skill. Strong collaboration is welcome, but the core expectation is leadership of a high-caliber research program. That distinction is important in a research environment built around cross-disciplinary facilities: shared infrastructure can accelerate discovery, but only if principal investigators can define a focused scientific agenda and use the tools selectively rather than diffusely.
A second practical point stands out. The institute-level hiring strategy is designed to attract scientists who can cross from fundamental mechanism into translational research without losing rigor at either end.
What the Recruitment Window Says About Institutional Priorities
The positions are open on a rolling basis until filled, which is typical for faculty searches that are trying to match scientific fit with institutional growth rather than fill a fixed headcount quickly. The structure of the announcement suggests a university investing in domains with long-term relevance to human health: immune-mediated disease, infectious disease, structural biology, computational methods, and drug discovery. Those areas also overlap with the kinds of research infrastructure China has been building at scale, especially where biology, engineering, and data science intersect.
For applicants, the message is straightforward. ShanghaiTech is looking for researchers who can build labs, teach, and produce science that moves beyond observation toward intervention. For the institution, the recruitment drive is a way to shape the next phase of its biomedical identity around mechanisms that can be interrogated, modeled, and ultimately targeted.
The open question is not whether the university has assembled an ambitious wish list. It is whether the new faculty cohort can convert that breadth of expertise into sustained output across immunology, GPCR biology, structural methods, and therapeutic discovery.